Insider Selling: AnaptysBio Inc (NASDAQ:ANAB) CEO Sells 22,428 Shares of Stock

AnaptysBio Inc (NASDAQ:ANAB) CEO Hamza Suria sold 22,428 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total value of $1,654,289.28. Following the transaction, the chief executive officer now directly owns 31,524 shares of the company’s stock, valued at approximately $2,325,210.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ANAB stock traded up $0.54 during midday trading on Wednesday, hitting $74.07. The company had a trading volume of 315,732 shares, compared to its average volume of 251,802. AnaptysBio Inc has a 52 week low of $54.26 and a 52 week high of $110.00. The company has a market capitalization of $1.99 billion, a P/E ratio of -29.63 and a beta of 1.97.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. On average, equities analysts forecast that AnaptysBio Inc will post -3.63 EPS for the current year.



Several analysts have issued reports on ANAB shares. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “buy” rating and set a $77.00 target price for the company in a research note on Wednesday, March 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $140.00 price objective on shares of AnaptysBio in a research report on Wednesday, February 27th. Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a research report on Friday, March 1st. Stifel Nicolaus set a $124.00 price objective on AnaptysBio and gave the company a “buy” rating in a research report on Wednesday, May 8th. Finally, Guggenheim began coverage on AnaptysBio in a research report on Friday, February 22nd. They issued a “buy” rating and a $135.00 price objective for the company. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $123.42.

Several institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System raised its holdings in shares of AnaptysBio by 1.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 10,147 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 140 shares in the last quarter. SEI Investments Co raised its holdings in shares of AnaptysBio by 1.7% during the first quarter. SEI Investments Co now owns 11,171 shares of the biotechnology company’s stock valued at $816,000 after acquiring an additional 187 shares in the last quarter. United Services Automobile Association raised its holdings in shares of AnaptysBio by 6.2% during the fourth quarter. United Services Automobile Association now owns 4,647 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 271 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in shares of AnaptysBio by 14.5% during the first quarter. Dynamic Technology Lab Private Ltd now owns 3,983 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 503 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new position in shares of AnaptysBio during the fourth quarter valued at approximately $38,000.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/06/12/insider-selling-anaptysbio-inc-nasdaqanab-ceo-sells-22428-shares-of-stock.html.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Article: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.